As the biggest and brightest in the blood cancer world came together for the ASH conference this weekend, European biotech Argenx was busy making a big biobucks deal.
It has teamed up with Cilag, a subsidiary of Janssen, to work on the company’s cusatuzumab.
Copyright © 2020,